INNT Innovate Biopharmaceuticals Inc.

1.15
-0.02  -2%
Previous Close 1.17
Open 1.17
Price To Book 8.21
Market Cap 41,266,546
Shares 35,883,953
Volume 39,357
Short Ratio
Av. Daily Volume 178,789

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned.
INN-108
Ulcerative colitis
Phase 3 initiation of dosing announced August 13, 2019.
INN-202
Celiac disease
Phase 2 to be initiated in 2019.
Larazotide acetate
Nonalcoholic steatohepatitis (NASH)